Holen Sie sich die Stockscreener-App
36.13
11.03%
-4.48
Handel nachbörslich:
36.24
0.11
+0.30%
Schlusskurs vom Vortag:
$40.61
Offen:
$35
24-Stunden-Volumen:
3.13M
Relative Volume:
4.08
Marktkapitalisierung:
$2.10B
Einnahmen:
$32.87M
Nettoeinkommen (Verlust:
$674.31M
KGV:
3.1805
EPS:
11.36
Netto-Cashflow:
$-330.11M
1W Leistung:
-5.37%
1M Leistung:
-0.08%
6M Leistung:
+8.21%
1J Leistung:
-19.26%
1-Tages-Spanne:
$32.70
$36.35
1-Wochen-Bereich:
$32.70
$41.10
52-Wochen-Spanne:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie AGIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
36.13 | 2.28B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
Liver Injury REMS Delays Agios’s Pyrukynd US FDA Approval In Thalassemia - insights.citeline.com
Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated - Seeking Alpha
FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use - Benzinga
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More - MSN
Agios Pharmaceuticals shares fall 13.52% intraday after FDA delays PDUFA target date for PYRUKYND. - AInvest
FDA delays decision on Agios drug in thalassemia over liver safety - Endpoints News
Agios drops as FDA delays review of thalassemia drug - MSN
Why Did Agios Plunge 26.94%? FDA Delays PYRUKYND Review - AInvest
Agios Pharmaceuticals and the FDA Delay for Pyrukynd in Thalassemia: Assessing the Materiality of Safety Concerns and REMS Submission on Commercial Potential and Stock Valuation - AInvest
Agios stock drops as FDA delays Pyrukynd review (AGIO:NASDAQ) - Seeking Alpha
FDA Extends Review of First Oral Treatment for Thalassemia: Agios' PYRUKYND Decision Set for December - Stock Titan
Agios Pharmaceuticals Inc.’s volatility index tracking explained2025 Top Gainers & AI Enhanced Trading Alerts - Newser
Is Agios Pharmaceuticals Inc. stock ready for a breakout2025 Analyst Calls & Trade Opportunity Analysis Reports - Newser
Is Agios Pharmaceuticals Inc. trending in predictive chart models2025 AllTime Highs & Daily Volume Surge Trade Alerts - Newser
Should you hold or exit Agios Pharmaceuticals Inc. nowJuly 2025 EndofMonth & Real-Time Volume Triggers - Newser
Is Agios Pharmaceuticals Inc. still worth holding after the dip2025 Market WrapUp & AI Based Buy and Sell Signals - Newser
Full technical analysis of Agios Pharmaceuticals Inc. stockTrade Volume Summary & Verified Swing Trading Watchlist - Newser
Statistical indicators supporting Agios Pharmaceuticals Inc.’s strengthRate Hike & Consistent Income Trade Ideas - Newser
How to forecast Agios Pharmaceuticals Inc. trends using time seriesM&A Rumor & Fast Entry Momentum Alerts - Newser
Is Agios Pharmaceuticals Inc. undervalued by DCF analysisMarket Sentiment Review & Reliable Momentum Entry Alerts - khodrobank.com
Should you wait for a breakout in Agios Pharmaceuticals Inc.2025 Retail Activity & Fast Exit Strategy with Risk Control - Newser
Price action breakdown for Agios Pharmaceuticals Inc.Portfolio Value Summary & High Yield Stock Recommendations - Newser
Long term hold vs stop loss in Agios Pharmaceuticals Inc.Treasury Yields & Daily Chart Pattern Signal Reports - Newser
What MACD signals say about Agios Pharmaceuticals Inc.Weekly Stock Recap & Technical Buy Zone Confirmations - Newser
Developing predictive dashboards with Agios Pharmaceuticals Inc. dataIndex Update & Fast Momentum Entry Tips - Newser
Historical volatility pattern of Agios Pharmaceuticals Inc. visualizedEarnings Growth Summary & Daily Technical Forecast Reports - Newser
Chart Patterns Forming a Bullish Setup in Agios Pharmaceuticals Inc.Sell Signal & Free High Return Stock Watch Alerts - beatles.ru
Can trapped investors hope for a rebound in Agios Pharmaceuticals Inc.Trade Volume Report & Weekly Stock Breakout Alerts - Newser
How to track smart money flows in Agios Pharmaceuticals Inc.July 2025 Snapshot & Capital Efficient Trading Techniques - Newser
Can Agios Pharmaceuticals Inc. deliver consistent EPS growthWeekly Stock Recap & Weekly High Return Stock Opportunities - khodrobank.com
Is Agios Pharmaceuticals Inc. a turnaround storyJuly 2025 Summary & High Accuracy Investment Entry Signals - khodrobank.com
Commit To Buy Agios Pharmaceuticals At $30, Earn 34.9% Annualized Using Options - Nasdaq
Detecting support and resistance levels for Agios Pharmaceuticals Inc.Dollar Strength & Fast Moving Stock Trade Plans - Newser
Using AI based signals to follow Agios Pharmaceuticals Inc.Quarterly Trade Review & High Accuracy Trade Alerts - Newser
What moving averages say about Agios Pharmaceuticals Inc.Watch List & Safe Capital Investment Plans - Newser
Long term hold vs stop loss in Agios Pharmaceuticals Inc2025 Biggest Moves & Daily Stock Trend Watchlist - Newser
Will Agios Pharmaceuticals Inc. benefit from sector rotation2025 Buyback Activity & AI Powered Market Entry Ideas - khodrobank.com
Earnings Beat: Does Agios Pharmaceuticals Inc. outperform in volatile marketsCPI Data & Daily Risk Controlled Trade Plans - khodrobank.com
Combining machine learning predictions for Agios Pharmaceuticals Inc.2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - Newser
Will Agios Pharmaceuticals Inc. outperform tech stocksTrade Risk Summary & Community Driven Trade Alerts - khodrobank.com
Does Agios Pharmaceuticals Inc. stock reflect fundamentalsWeekly Loss Report & Technical Confirmation Alerts - khodrobank.com
Has Agios Pharmaceuticals Inc. found a price floorMarket Sentiment Review & Precise Buy Zone Identification - Newser
Does Agios Pharmaceuticals Inc. show high probability of rebound2025 Top Gainers & Community Verified Swing Trade Signals - Newser
Chart based exit strategy for Agios Pharmaceuticals Inc.2025 Fundamental Recap & Free Fast Entry Momentum Trade Alerts - Newser
What technical models suggest about Agios Pharmaceuticals Inc.’s comeback - Newser
Is Agios Pharmaceuticals Inc. stock poised for growth2025 Performance Recap & Community Verified Watchlist Alerts - Newser
Published on: 2025-08-31 15:38:48 - Newser
Exit strategy if you’re trapped in Agios Pharmaceuticals Inc.Quarterly Profit Report & AI Optimized Trade Strategies - Newser
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Agios Pharmaceuticals Inc-Aktie (AGIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Scadden David | Director |
Aug 27 '25 |
Sale |
40.00 |
200 |
8,000 |
17,603 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):